Creative Biolabs provides cardiovascular disease microbiome research and preclinical probiotic CRO services, helping R&D teams connect candidate strains with phenotype-specific efficacy, metabolite mechanisms, and safety evidence. Our integrated approach combines microbial characterization, cardiometabolic models, short-chain fatty acid testing, metabolomics, and inflammatory readouts to support informed development decisions across hypertension, atherosclerosis, and related indications.
Cardiovascular phenotypes do not share one microbiome mechanism. Blood-pressure regulation, lipid-associated plaque formation, and post-ischemic recovery can involve different host pathways, microbial communities, and circulating metabolites. For cardiovascular biotech, metabolic microbiome developers, and functional nutrition R&D teams, a uniform probiotic screening assay can therefore miss the biology that matters most to a particular program.
A useful development plan links a defined strain or microbial function to measurable host outcomes while controlling for diet, baseline microbiota, and model context. Creative Biolabs supports that translation with integrated microbiome mapping, strain-level functional testing, targeted metabolite analysis, and indication-matched preclinical studies—so promising signals can be challenged, prioritized, and interpreted with appropriate safeguards.
Mechanistic research axis
Coherent evidence connects changes in microbial function with relevant cardiovascular endpoints.
Integrate blood pressure profiles, vascular reactivity, sodium-handling biology, and microbial metabolite exposure.
Relate lipid panels and lesion biology to inflammatory signaling, barrier function, and selected metabolite pathways.
Where indicated, examine tissue injury, cardiac function, systemic inflammation, and post-injury microbial ecology.
We align each work package with a defined cardiovascular phenotype and decision point, instead of assuming that the same bacterial endpoint predicts every disease outcome. Study modules can be commissioned individually or combined into a connected research program.
Characterize disease-associated microbial patterns and nominate candidates based on biologically justified pathways rather than species abundance alone. Molecular data can be integrated with clinical covariates or preclinical phenotype strata when available.
Progress from a taxonomy label to an evaluable biological candidate. Creative Biolabs can assess strain identity, functional properties, and potential hazards relevant to the intended research setting.
Choose an established cardiometabolic model or a customized design according to the primary question and feasibility. Measures are prespecified with suitable controls and consideration of sex, diet, microbiota background, and time course.
Determine whether microbial changes correspond to a measurable biochemical pathway and host effect. Targeted and discovery-level metabolite data help separate pathway plausibility from unsupported efficacy claims.
With compatible work packages, we can support the transition from candidate discovery to model-based efficacy and mechanistic investigation in a single coordinated study plan.
The original cardiovascular research scope highlights lactic acid bacteria and bifidobacteria in lipid and blood-pressure studies. These organisms are starting points for strain-specific verification—not interchangeable cardiovascular therapeutics.
Investigated in metabolic and fermented-food research; screening should confirm strain-specific lipid, metabolite, and immune phenotypes.
A candidate for testing dietary lipid-related activity and inflammatory mechanisms, with outcomes dependent on the selected strain.
Fermented-food and bioactive peptide hypotheses can be evaluated in controlled assays; antihypertensive potential cannot be generalized across strains.
Primarily a fermented-food starter organism; relevant studies require product-context assessment and organism-specific safety considerations.
Includes strains considered in lipid metabolism and gut-barrier studies. Candidate identity and the metabolite mechanism should be verified directly.
Butyrate-associated community members can serve as functional or ecological research signals; abundance does not imply intervention efficacy.
A prespecified endpoint plan links each research question to an assay, biological matrix, appropriate controls, and the next development decision. The exact panel is tailored to the chosen model.
| Research question | Illustrative readouts | Deliverable / decision |
|---|---|---|
| Does the microbiome respond? | 16S or metagenomic profiles; strain tracking; community function; time-course sampling | Ecological exposure and response profile |
| Does microbial metabolism shift? | Acetate, propionate, butyrate; optional bile acids, tryptophan metabolites, TMAO-related markers | Targeted pathway evidence and metabolite priority list |
| Does a cardiovascular phenotype change? | Blood pressure; cholesterol fractions; vascular lesions; selected cardiac functional measures | Phenotype-specific efficacy assessment |
| Are inflammatory pathways affected? | TNF-α, IL-6, oxidative stress, endothelial or barrier-associated endpoints as indicated | Mechanistic response and context-dependent interpretation |
| Is the candidate suitable to advance? | Strain identity, microbial quality, genomic hazards, susceptibility, tolerability, exposure | Integrated safety observations and next-step decision |
Assay availability, sample matrices, acceptance criteria, and endpoint selection are specified for each project; the listed outcomes are research endpoints, not guaranteed clinical effects.
Specify target indication, hypothesis, matrix, comparators, and success criteria.
Authenticate candidate strains; profile the microbiome and baseline function.
Choose cardiometabolic models, study arms, dosing, and sampling time points.
Capture efficacy, inflammatory, vascular, and tolerability endpoints.
Integrate SCFAs, metabolomics, and organism-level findings.
Deliver interpreted datasets, study limitations, and next-step options.
At every phase, a defined decision gate connects assay performance and biological plausibility with the next planned experiment, reducing fragmented readouts and premature conclusions.
Recently published research investigated whether a defined Lactobacillus johnsonii strain could modify gut microbiota and host outcomes in a rat model of acute myocardial infarction. The investigators linked echocardiography, tissue pathology, intestinal barrier measures, microbial composition, and circulating metabolites. Their experimental findings showed differences in cardiac function and inflammatory injury markers alongside microbial remodeling following strain administration. Importantly, the results came from a preclinical rat model and cannot be assumed to predict human cardiovascular benefit.
These findings illustrate why cardiovascular probiotic programs benefit from coordinated strain, metabolite, and host-phenotype assessment rather than relying on microbiome abundance changes alone. Creative Biolabs supports this evidence-building approach through candidate screening, phenotype-matched animal studies, targeted SCFA analysis, broader metabolomics, and safety-oriented study planning. Research designs can test whether shifts in intestinal barrier and metabolite signatures accompany meaningful, reproducible host outcomes, while separating mechanistic association from causal demonstration.

Models and endpoints follow the cardiovascular question rather than a generic gut-health readout.
Microbiome, targeted metabolites, and host biology are measured within a coherent plan.
Identity and function checkpoints make results traceable to an actual candidate organism.
Potential SCFA, inflammatory, and barrier pathways are tested against predefined outcomes.
Clear controls, QA, study limitations, and decision criteria support program reviews.
Targeted standalone analytics or integrated end-to-end work packages can be scoped.
These related services can be combined with the core cardiovascular program to add model-specific efficacy evaluation, targeted SCFA measures, broader metabolic profiling, and mechanism-linked analytics.
Model selection and cardiometabolic phenotyping
Mechanism-linked metabolite and host-response studies
Targeted acetate, propionate, and butyrate endpoints
Untargeted discovery and targeted metabolite follow-up
We first define the primary phenotype—blood pressure regulation, dyslipidemia or atherosclerosis, or post-ischemic remodeling—then select models, exposure windows, comparators, and endpoints matched to that question. Microbiome composition and metabolite profiles are interpreted alongside host outcomes rather than being treated as efficacy evidence on their own.
Targeted panels can quantify acetate, propionate, and butyrate in fecal or biological matrices appropriate to the study. Broader profiling may include bile acids, amino acid-derived products, and trimethylamine N-oxide (TMAO) where method suitability and matrix validation support the assay. We predefine normalization, quality controls, and the limits of interpretation.
Yes. Candidate strains can undergo identity confirmation, genomic and safety review, functional screening, and carefully controlled preclinical evaluation. Species-level associations do not establish strain-specific cardiovascular benefit; evidence is generated separately for each proposed strain and indication.
Controls can include vehicle and model controls, baseline samples, a justified positive comparator, and appropriate dietary or exposure standardization. Where mechanistic attribution matters, additional microbiota-perturbation or metabolite-rescue arms may be considered if scientifically suitable.
Study planning can include strain identity, antimicrobial susceptibility and relevant genomic hazards, tolerability, microbial translocation or barrier endpoints where indicated, plus dose and exposure tracking. The resulting evidence supports a research go/no-go decision; it does not itself demonstrate clinical safety or treatment efficacy.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2026 Creative Biolabs. All Rights Reserved.